Novoheart (TSXV: NVH)(FWB: 3NH) is a global stem cell biotechnology company pioneering an array of next-generation human heart tissue prototypes. It is the first and only company in the world to have engineered miniature living human heart pumps that can revolutionize drug discovery, helping to save time and money for developing new therapeutics. Also known as 'human heart-in-a-jar'
…More;, Novoheart’s bio-artificial human heart constructs are created using state-of-the-art and proprietary stem cell and bioengineering approaches and are utilized by global pharmaceutical and biotech companies for accurate preclinical testing as to the effectiveness and safety of new drugs, maximizing the successes in drug discovery whilst minimizing costs and harm caused to patients. Novoheart currently has corporate offices and laboratories in the United States, Canada, and Hong Kong.